In RRMS, the early course of the disease is characterised by intermittent relapses, and partial or complete recovery of function between exacerbations. The occurrence of relapses is a key measure of ...
Demonstrates Additive Anti-Cancer Effect in Bladder Cancer In-Vitro Model when Light-Activated Ruvidar(R) is Combined with InterferonToronto, Ontario--(Newsfile Corp. - March 2, 2026) - Theralase® ...
The FDA gave positive feedback regarding filing a Biologics License Application (BLA) for Sjögren's syndrome following two Phase 3 studies Ainos is seeking out-licensing opportunities to accelerate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results